Quantitative Assessment of the Efficacy of Near-Infrared Photoimmunotherapy with Bioluminescence Imaging

Ryuhei Okada; Aki Furusawa; Peter L Choyke; Hisataka Kobayashi

doi:10.1007/978-1-0716-2473-9_1

Quantitative Assessment of the Efficacy of Near-Infrared Photoimmunotherapy with Bioluminescence Imaging

Methods Mol Biol. 2022:2525:3-13. doi: 10.1007/978-1-0716-2473-9_1.

Authors

Ryuhei Okada¹, Aki Furusawa¹, Peter L Choyke¹, Hisataka Kobayashi²

Affiliations

¹ Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
² Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. kobayash@mail.nih.gov.

PMID: 35836056
DOI: 10.1007/978-1-0716-2473-9_1

Abstract

Near-infrared photoimmunotherapy (NIR-PIT) is a cell-specific cancer therapy in which antibody-photoabsorber conjugates (APCs) are activated by NIR light to induce rapid immunogenic cell death with minimal off-target effects. In preclinical settings, bioluminescence imaging (BLI) is useful to quantitatively assess the efficacy of NIR-PIT for both in vitro and in vivo experiments, especially in the early phase of testing. Here, we describe the detailed methods of the experiments for NIR-PIT and evaluation of its efficacy using BLI.

Keywords: BLI; Firefly; Luciferase; Luciferin; NIR-PIT.

Publication types

Research Support, N.I.H., Intramural

MeSH terms

Cell Line, Tumor
Humans
Immunoconjugates* / pharmacology
Immunogenic Cell Death
Immunotherapy / methods
Neoplasms* / drug therapy
Phototherapy / methods
Xenograft Model Antitumor Assays

Substances

Immunoconjugates